CN103052632A - 二氢吡唑类化合物 - Google Patents
二氢吡唑类化合物 Download PDFInfo
- Publication number
- CN103052632A CN103052632A CN2011800317815A CN201180031781A CN103052632A CN 103052632 A CN103052632 A CN 103052632A CN 2011800317815 A CN2011800317815 A CN 2011800317815A CN 201180031781 A CN201180031781 A CN 201180031781A CN 103052632 A CN103052632 A CN 103052632A
- Authority
- CN
- China
- Prior art keywords
- alkyl
- cycloalkyl
- hydroxyl
- halogen atom
- optionally
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- KEQTWHPMSVAFDA-UHFFFAOYSA-N 2,3-dihydro-1h-pyrazole Chemical class C1NNC=C1 KEQTWHPMSVAFDA-UHFFFAOYSA-N 0.000 title 1
- -1 dihydropyrazole compound Chemical class 0.000 claims abstract description 125
- 150000001875 compounds Chemical class 0.000 claims abstract description 70
- 150000003839 salts Chemical class 0.000 claims abstract description 49
- 238000002360 preparation method Methods 0.000 claims abstract description 41
- 206010020772 Hypertension Diseases 0.000 claims abstract description 11
- 208000030172 endocrine system disease Diseases 0.000 claims abstract description 7
- 239000000825 pharmaceutical preparation Substances 0.000 claims abstract description 7
- 125000000217 alkyl group Chemical group 0.000 claims description 155
- 125000005843 halogen group Chemical group 0.000 claims description 140
- 125000000623 heterocyclic group Chemical group 0.000 claims description 112
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 108
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims description 104
- 125000001424 substituent group Chemical group 0.000 claims description 91
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 73
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 69
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 65
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 59
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 44
- 125000000081 (C5-C8) cycloalkenyl group Chemical group 0.000 claims description 41
- 125000003368 amide group Chemical group 0.000 claims description 41
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical class OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 32
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 32
- 125000003545 alkoxy group Chemical group 0.000 claims description 31
- HDOWRFHMPULYOA-UHFFFAOYSA-N piperidin-4-ol Chemical compound OC1CCNCC1 HDOWRFHMPULYOA-UHFFFAOYSA-N 0.000 claims description 31
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims description 30
- 125000003282 alkyl amino group Chemical group 0.000 claims description 25
- 125000005936 piperidyl group Chemical group 0.000 claims description 25
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 24
- 229910052757 nitrogen Inorganic materials 0.000 claims description 23
- 125000002252 acyl group Chemical group 0.000 claims description 22
- 230000015572 biosynthetic process Effects 0.000 claims description 22
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims description 21
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 21
- 125000006625 (C3-C8) cycloalkyloxy group Chemical group 0.000 claims description 19
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 claims description 18
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims description 18
- 125000004429 atom Chemical group 0.000 claims description 17
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 17
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 17
- 150000001335 aliphatic alkanes Chemical class 0.000 claims description 16
- 210000003734 kidney Anatomy 0.000 claims description 16
- 125000003277 amino group Chemical group 0.000 claims description 15
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 15
- JUJWROOIHBZHMG-UHFFFAOYSA-N pyridine Substances C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims description 15
- 238000006467 substitution reaction Methods 0.000 claims description 15
- 125000005422 alkyl sulfonamido group Chemical group 0.000 claims description 14
- 230000006378 damage Effects 0.000 claims description 14
- 125000003342 alkenyl group Chemical group 0.000 claims description 13
- 125000004448 alkyl carbonyl group Chemical group 0.000 claims description 13
- 239000003814 drug Substances 0.000 claims description 13
- 208000027418 Wounds and injury Diseases 0.000 claims description 12
- 125000004390 alkyl sulfonyl group Chemical group 0.000 claims description 12
- 125000000304 alkynyl group Chemical group 0.000 claims description 12
- 208000014674 injury Diseases 0.000 claims description 12
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 12
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 11
- 229910052801 chlorine Inorganic materials 0.000 claims description 10
- 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 claims description 10
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims description 10
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 9
- 125000003118 aryl group Chemical group 0.000 claims description 9
- 125000000392 cycloalkenyl group Chemical group 0.000 claims description 9
- 239000007789 gas Substances 0.000 claims description 9
- 229910052736 halogen Inorganic materials 0.000 claims description 9
- 125000005196 alkyl carbonyloxy group Chemical group 0.000 claims description 8
- 125000001188 haloalkyl group Chemical group 0.000 claims description 8
- 125000006704 (C5-C6) cycloalkyl group Chemical group 0.000 claims description 7
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 7
- 150000002367 halogens Chemical class 0.000 claims description 7
- 239000003112 inhibitor Substances 0.000 claims description 7
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims description 7
- 125000004454 (C1-C6) alkoxycarbonyl group Chemical group 0.000 claims description 6
- 102000003729 Neprilysin Human genes 0.000 claims description 6
- 108090000028 Neprilysin Proteins 0.000 claims description 6
- 239000005864 Sulphur Substances 0.000 claims description 6
- 125000004414 alkyl thio group Chemical group 0.000 claims description 6
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 6
- 229940079593 drug Drugs 0.000 claims description 6
- 229910052731 fluorine Inorganic materials 0.000 claims description 6
- 125000001153 fluoro group Chemical group F* 0.000 claims description 6
- 125000001072 heteroaryl group Chemical group 0.000 claims description 6
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims description 5
- 125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 claims description 5
- 208000011580 syndromic disease Diseases 0.000 claims description 5
- 230000001225 therapeutic effect Effects 0.000 claims description 5
- 125000004916 (C1-C6) alkylcarbonyl group Chemical group 0.000 claims description 4
- 229940127291 Calcium channel antagonist Drugs 0.000 claims description 4
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical group [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 4
- 239000013543 active substance Substances 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 4
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 4
- 206010016654 Fibrosis Diseases 0.000 claims description 3
- 206010019280 Heart failures Diseases 0.000 claims description 3
- 201000010099 disease Diseases 0.000 claims description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 3
- 230000004761 fibrosis Effects 0.000 claims description 3
- 239000001257 hydrogen Substances 0.000 claims description 3
- 229910052739 hydrogen Inorganic materials 0.000 claims description 3
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 claims description 3
- 208000026872 Addison Disease Diseases 0.000 claims description 2
- 206010002383 Angina Pectoris Diseases 0.000 claims description 2
- 208000006029 Cardiomegaly Diseases 0.000 claims description 2
- 229940118365 Endothelin receptor antagonist Drugs 0.000 claims description 2
- 108090000790 Enzymes Proteins 0.000 claims description 2
- 102000004190 Enzymes Human genes 0.000 claims description 2
- 206010061216 Infarction Diseases 0.000 claims description 2
- 102000003979 Mineralocorticoid Receptors Human genes 0.000 claims description 2
- 108090000375 Mineralocorticoid Receptors Proteins 0.000 claims description 2
- 208000009525 Myocarditis Diseases 0.000 claims description 2
- 108090000861 alpha Adrenergic Receptors Proteins 0.000 claims description 2
- 102000004305 alpha Adrenergic Receptors Human genes 0.000 claims description 2
- 125000004202 aminomethyl group Chemical group [H]N([H])C([H])([H])* 0.000 claims description 2
- 230000003178 anti-diabetic effect Effects 0.000 claims description 2
- 239000003472 antidiabetic agent Substances 0.000 claims description 2
- 206010003119 arrhythmia Diseases 0.000 claims description 2
- 210000001124 body fluid Anatomy 0.000 claims description 2
- 239000010839 body fluid Substances 0.000 claims description 2
- 239000000480 calcium channel blocker Substances 0.000 claims description 2
- 239000003354 cholesterol ester transfer protein inhibitor Substances 0.000 claims description 2
- 229940125881 cholesteryl ester transfer protein inhibitor Drugs 0.000 claims description 2
- 208000025302 chronic primary adrenal insufficiency Diseases 0.000 claims description 2
- 230000004064 dysfunction Effects 0.000 claims description 2
- 230000002526 effect on cardiovascular system Effects 0.000 claims description 2
- 239000002308 endothelin receptor antagonist Substances 0.000 claims description 2
- 230000007574 infarction Effects 0.000 claims description 2
- 239000004041 inotropic agent Substances 0.000 claims description 2
- 239000012528 membrane Substances 0.000 claims description 2
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 210000001774 pressoreceptor Anatomy 0.000 claims description 2
- 239000003087 receptor blocking agent Substances 0.000 claims description 2
- 108091006082 receptor inhibitors Proteins 0.000 claims description 2
- 102100030988 Angiotensin-converting enzyme Human genes 0.000 claims 2
- JMANVNJQNLATNU-UHFFFAOYSA-N oxalonitrile Chemical compound N#CC#N JMANVNJQNLATNU-UHFFFAOYSA-N 0.000 claims 2
- 125000006700 (C1-C6) alkylthio group Chemical group 0.000 claims 1
- UUUHXMGGBIUAPW-UHFFFAOYSA-N 1-[1-[2-[[5-amino-2-[[1-[5-(diaminomethylideneamino)-2-[[1-[3-(1h-indol-3-yl)-2-[(5-oxopyrrolidine-2-carbonyl)amino]propanoyl]pyrrolidine-2-carbonyl]amino]pentanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-methylpentanoyl]pyrrolidine-2-carbon Chemical compound C1CCC(C(=O)N2C(CCC2)C(O)=O)N1C(=O)C(C(C)CC)NC(=O)C(CCC(N)=O)NC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C1CCCN1C(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C1CCC(=O)N1 UUUHXMGGBIUAPW-UHFFFAOYSA-N 0.000 claims 1
- 229940123413 Angiotensin II antagonist Drugs 0.000 claims 1
- 108090000854 Oxidoreductases Proteins 0.000 claims 1
- 102000004316 Oxidoreductases Human genes 0.000 claims 1
- 108090000882 Peptidyl-Dipeptidase A Proteins 0.000 claims 1
- 108091007187 Reductases Proteins 0.000 claims 1
- 150000003973 alkyl amines Chemical class 0.000 claims 1
- 239000002333 angiotensin II receptor antagonist Substances 0.000 claims 1
- 150000002118 epoxides Chemical class 0.000 claims 1
- 208000024172 Cardiovascular disease Diseases 0.000 abstract 1
- 206010061481 Renal injury Diseases 0.000 abstract 1
- 239000002585 base Substances 0.000 description 275
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 48
- 238000006243 chemical reaction Methods 0.000 description 48
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 36
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 36
- JFDZBHWFFUWGJE-UHFFFAOYSA-N benzonitrile Chemical compound N#CC1=CC=CC=C1 JFDZBHWFFUWGJE-UHFFFAOYSA-N 0.000 description 30
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 20
- 239000012043 crude product Substances 0.000 description 19
- 239000007787 solid Substances 0.000 description 18
- 125000002619 bicyclic group Chemical group 0.000 description 17
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 16
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 15
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 14
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 13
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 12
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 12
- 238000004440 column chromatography Methods 0.000 description 12
- 238000012805 post-processing Methods 0.000 description 12
- 239000011734 sodium Substances 0.000 description 11
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 10
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 10
- HONIICLYMWZJFZ-UHFFFAOYSA-N azetidine Chemical compound C1CNC1 HONIICLYMWZJFZ-UHFFFAOYSA-N 0.000 description 10
- 125000001047 cyclobutenyl group Chemical group C1(=CCC1)* 0.000 description 10
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 10
- 150000002825 nitriles Chemical class 0.000 description 10
- 238000012360 testing method Methods 0.000 description 10
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 9
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 9
- 239000012071 phase Substances 0.000 description 9
- 239000000047 product Substances 0.000 description 9
- 239000002904 solvent Substances 0.000 description 9
- 238000005406 washing Methods 0.000 description 9
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 8
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 8
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 8
- 239000002395 mineralocorticoid Substances 0.000 description 8
- 229910052708 sodium Inorganic materials 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- 239000007791 liquid phase Substances 0.000 description 7
- 108020003175 receptors Proteins 0.000 description 7
- 102000005962 receptors Human genes 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 6
- 238000001816 cooling Methods 0.000 description 6
- 238000005516 engineering process Methods 0.000 description 6
- 125000005842 heteroatom Chemical group 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 6
- TVMXDCGIABBOFY-UHFFFAOYSA-N octane Chemical compound CCCCCCCC TVMXDCGIABBOFY-UHFFFAOYSA-N 0.000 description 6
- 229930192474 thiophene Natural products 0.000 description 6
- PQSUYGKTWSAVDQ-ZVIOFETBSA-N Aldosterone Chemical compound C([C@@]1([C@@H](C(=O)CO)CC[C@H]1[C@@H]1CC2)C=O)[C@H](O)[C@@H]1[C@]1(C)C2=CC(=O)CC1 PQSUYGKTWSAVDQ-ZVIOFETBSA-N 0.000 description 5
- PQSUYGKTWSAVDQ-UHFFFAOYSA-N Aldosterone Natural products C1CC2C3CCC(C(=O)CO)C3(C=O)CC(O)C2C2(C)C1=CC(=O)CC2 PQSUYGKTWSAVDQ-UHFFFAOYSA-N 0.000 description 5
- 239000007821 HATU Substances 0.000 description 5
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 5
- 229960002478 aldosterone Drugs 0.000 description 5
- 229910052799 carbon Inorganic materials 0.000 description 5
- 238000001035 drying Methods 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 238000000605 extraction Methods 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 239000001301 oxygen Substances 0.000 description 5
- 229910052760 oxygen Inorganic materials 0.000 description 5
- FCEHBMOGCRZNNI-UHFFFAOYSA-N 1-benzothiophene Chemical compound C1=CC=C2SC=CC2=C1 FCEHBMOGCRZNNI-UHFFFAOYSA-N 0.000 description 4
- BKOOMYPCSUNDGP-UHFFFAOYSA-N 2-methylbut-2-ene Chemical compound CC=C(C)C BKOOMYPCSUNDGP-UHFFFAOYSA-N 0.000 description 4
- MCGBIXXDQFWVDW-UHFFFAOYSA-N 4,5-dihydro-1h-pyrazole Chemical compound C1CC=NN1 MCGBIXXDQFWVDW-UHFFFAOYSA-N 0.000 description 4
- CSDQQAQKBAQLLE-UHFFFAOYSA-N 4-(4-chlorophenyl)-4,5,6,7-tetrahydrothieno[3,2-c]pyridine Chemical compound C1=CC(Cl)=CC=C1C1C(C=CS2)=C2CCN1 CSDQQAQKBAQLLE-UHFFFAOYSA-N 0.000 description 4
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 125000004432 carbon atom Chemical group C* 0.000 description 4
- 229940125782 compound 2 Drugs 0.000 description 4
- 125000004122 cyclic group Chemical group 0.000 description 4
- CHVJITGCYZJHLR-UHFFFAOYSA-N cyclohepta-1,3,5-triene Chemical compound C1C=CC=CC=C1 CHVJITGCYZJHLR-UHFFFAOYSA-N 0.000 description 4
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 4
- NNBZCPXTIHJBJL-UHFFFAOYSA-N decalin Chemical compound C1CCCC2CCCCC21 NNBZCPXTIHJBJL-UHFFFAOYSA-N 0.000 description 4
- DIOQZVSQGTUSAI-UHFFFAOYSA-N decane Chemical compound CCCCCCCCCC DIOQZVSQGTUSAI-UHFFFAOYSA-N 0.000 description 4
- 125000003963 dichloro group Chemical group Cl* 0.000 description 4
- 235000011167 hydrochloric acid Nutrition 0.000 description 4
- 238000001819 mass spectrum Methods 0.000 description 4
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 4
- 231100000252 nontoxic Toxicity 0.000 description 4
- 230000003000 nontoxic effect Effects 0.000 description 4
- BKIMMITUMNQMOS-UHFFFAOYSA-N normal nonane Natural products CCCCCCCCC BKIMMITUMNQMOS-UHFFFAOYSA-N 0.000 description 4
- 239000012074 organic phase Substances 0.000 description 4
- 125000004430 oxygen atom Chemical group O* 0.000 description 4
- 239000003208 petroleum Substances 0.000 description 4
- RLOWWWKZYUNIDI-UHFFFAOYSA-N phosphinic chloride Chemical compound ClP=O RLOWWWKZYUNIDI-UHFFFAOYSA-N 0.000 description 4
- 125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 238000000967 suction filtration Methods 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 3
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 3
- 229910019142 PO4 Inorganic materials 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- 150000001412 amines Chemical class 0.000 description 3
- 230000008485 antagonism Effects 0.000 description 3
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 3
- 150000001721 carbon Chemical group 0.000 description 3
- 229910002092 carbon dioxide Inorganic materials 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 235000019441 ethanol Nutrition 0.000 description 3
- JEGUKCSWCFPDGT-UHFFFAOYSA-N h2o hydrate Chemical compound O.O JEGUKCSWCFPDGT-UHFFFAOYSA-N 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- 125000004836 hexamethylene group Chemical group [H]C([H])([*:2])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[*:1] 0.000 description 3
- 238000012544 monitoring process Methods 0.000 description 3
- 235000001968 nicotinic acid Nutrition 0.000 description 3
- 239000011664 nicotinic acid Substances 0.000 description 3
- ZCYXXKJEDCHMGH-UHFFFAOYSA-N nonane Chemical compound CCCC[CH]CCCC ZCYXXKJEDCHMGH-UHFFFAOYSA-N 0.000 description 3
- 125000002255 pentenyl group Chemical group C(=CCCC)* 0.000 description 3
- 239000010452 phosphate Substances 0.000 description 3
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 3
- 150000003254 radicals Chemical class 0.000 description 3
- 239000002994 raw material Substances 0.000 description 3
- 210000003296 saliva Anatomy 0.000 description 3
- QDRKDTQENPPHOJ-UHFFFAOYSA-N sodium ethoxide Chemical compound [Na+].CC[O-] QDRKDTQENPPHOJ-UHFFFAOYSA-N 0.000 description 3
- 125000004646 sulfenyl group Chemical group S(*)* 0.000 description 3
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 3
- 238000010792 warming Methods 0.000 description 3
- GWYPDXLJACEENP-UHFFFAOYSA-N 1,3-cycloheptadiene Chemical compound C1CC=CC=CC1 GWYPDXLJACEENP-UHFFFAOYSA-N 0.000 description 2
- NCADHSLPNSTDMJ-UHFFFAOYSA-N 1-[(2-methylpropan-2-yl)oxycarbonyl]azetidine-3-carboxylic acid Chemical class CC(C)(C)OC(=O)N1CC(C(O)=O)C1 NCADHSLPNSTDMJ-UHFFFAOYSA-N 0.000 description 2
- 238000005160 1H NMR spectroscopy Methods 0.000 description 2
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 2
- WUTIIZNUZXLPGK-UHFFFAOYSA-N C(C)OC=O.N1=CC=CC=C1 Chemical class C(C)OC=O.N1=CC=CC=C1 WUTIIZNUZXLPGK-UHFFFAOYSA-N 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 2
- 208000007342 Diabetic Nephropathies Diseases 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 206010029164 Nephrotic syndrome Diseases 0.000 description 2
- 108020005497 Nuclear hormone receptor Proteins 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Chemical compound C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 description 2
- 208000001647 Renal Insufficiency Diseases 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 2
- 150000003869 acetamides Chemical class 0.000 description 2
- DZBUGLKDJFMEHC-UHFFFAOYSA-N acridine Chemical compound C1=CC=CC2=CC3=CC=CC=C3N=C21 DZBUGLKDJFMEHC-UHFFFAOYSA-N 0.000 description 2
- NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical group C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 239000003513 alkali Substances 0.000 description 2
- 229910021529 ammonia Inorganic materials 0.000 description 2
- 239000005557 antagonist Substances 0.000 description 2
- 239000008346 aqueous phase Substances 0.000 description 2
- RDGCBYXMELVTLY-UHFFFAOYSA-N azetidine;2,2,2-trifluoroacetic acid Chemical compound C1CNC1.OC(=O)C(F)(F)F RDGCBYXMELVTLY-UHFFFAOYSA-N 0.000 description 2
- 125000002393 azetidinyl group Chemical group 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- XDFORSMZCYHNBG-UHFFFAOYSA-N benzonitrile;hydrochloride Chemical compound Cl.N#CC1=CC=CC=C1 XDFORSMZCYHNBG-UHFFFAOYSA-N 0.000 description 2
- 150000008359 benzonitriles Chemical class 0.000 description 2
- 125000004744 butyloxycarbonyl group Chemical group 0.000 description 2
- 150000001768 cations Chemical class 0.000 description 2
- 229940125904 compound 1 Drugs 0.000 description 2
- 229940125773 compound 10 Drugs 0.000 description 2
- 229940126214 compound 3 Drugs 0.000 description 2
- 208000033679 diabetic kidney disease Diseases 0.000 description 2
- 229940113088 dimethylacetamide Drugs 0.000 description 2
- JUKPWJGBANNWMW-VWBFHTRKSA-N eplerenone Chemical compound C([C@@H]1[C@]2(C)C[C@H]3O[C@]33[C@@]4(C)CCC(=O)C=C4C[C@H]([C@@H]13)C(=O)OC)C[C@@]21CCC(=O)O1 JUKPWJGBANNWMW-VWBFHTRKSA-N 0.000 description 2
- 229960001208 eplerenone Drugs 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- MMXKVMNBHPAILY-UHFFFAOYSA-N ethyl laurate Chemical compound CCCCCCCCCCCC(=O)OCC MMXKVMNBHPAILY-UHFFFAOYSA-N 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- RWTNPBWLLIMQHL-UHFFFAOYSA-N fexofenadine Chemical compound C1=CC(C(C)(C(O)=O)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 RWTNPBWLLIMQHL-UHFFFAOYSA-N 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- LELOWRISYMNNSU-UHFFFAOYSA-N hydrogen cyanide Chemical compound N#C LELOWRISYMNNSU-UHFFFAOYSA-N 0.000 description 2
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 2
- 125000000904 isoindolyl group Chemical class C=1(NC=C2C=CC=CC12)* 0.000 description 2
- ZLVXBBHTMQJRSX-VMGNSXQWSA-N jdtic Chemical compound C1([C@]2(C)CCN(C[C@@H]2C)C[C@H](C(C)C)NC(=O)[C@@H]2NCC3=CC(O)=CC=C3C2)=CC=CC(O)=C1 ZLVXBBHTMQJRSX-VMGNSXQWSA-N 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 208000009928 nephrosis Diseases 0.000 description 2
- 231100001027 nephrosis Toxicity 0.000 description 2
- 125000004433 nitrogen atom Chemical group N* 0.000 description 2
- 102000006255 nuclear receptors Human genes 0.000 description 2
- 108020004017 nuclear receptors Proteins 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 125000002971 oxazolyl group Chemical group 0.000 description 2
- 239000012188 paraffin wax Substances 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 2
- 229940075930 picrate Drugs 0.000 description 2
- OXNIZHLAWKMVMX-UHFFFAOYSA-M picrate anion Chemical compound [O-]C1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O OXNIZHLAWKMVMX-UHFFFAOYSA-M 0.000 description 2
- FTMVNUGLWHCBJK-UHFFFAOYSA-N piperidin-1-ium;2,2,2-trifluoroacetate Chemical compound C1CCNCC1.OC(=O)C(F)(F)F FTMVNUGLWHCBJK-UHFFFAOYSA-N 0.000 description 2
- 150000003053 piperidines Chemical class 0.000 description 2
- 229950010765 pivalate Drugs 0.000 description 2
- IUGYQRQAERSCNH-UHFFFAOYSA-N pivalic acid Chemical compound CC(C)(C)C(O)=O IUGYQRQAERSCNH-UHFFFAOYSA-N 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 150000003222 pyridines Chemical class 0.000 description 2
- 150000003235 pyrrolidines Chemical class 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 229960002256 spironolactone Drugs 0.000 description 2
- LXMSZDCAJNLERA-ZHYRCANASA-N spironolactone Chemical compound C([C@@H]1[C@]2(C)CC[C@@H]3[C@@]4(C)CCC(=O)C=C4C[C@H]([C@@H]13)SC(=O)C)C[C@@]21CCC(=O)O1 LXMSZDCAJNLERA-ZHYRCANASA-N 0.000 description 2
- 230000003637 steroidlike Effects 0.000 description 2
- 239000004575 stone Substances 0.000 description 2
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 2
- 238000004808 supercritical fluid chromatography Methods 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 2
- QUERMGFVJPRMJL-UHFFFAOYSA-N tert-butyl azetidine-1-carboxylate Chemical class CC(C)(C)OC(=O)N1CCC1 QUERMGFVJPRMJL-UHFFFAOYSA-N 0.000 description 2
- RQCNHUCCQJMSRG-UHFFFAOYSA-N tert-butyl piperidine-1-carboxylate Chemical class CC(C)(C)OC(=O)N1CCCCC1 RQCNHUCCQJMSRG-UHFFFAOYSA-N 0.000 description 2
- 150000003512 tertiary amines Chemical class 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 238000001890 transfection Methods 0.000 description 2
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 2
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 2
- NWZSZGALRFJKBT-KNIFDHDWSA-N (2s)-2,6-diaminohexanoic acid;(2s)-2-hydroxybutanedioic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O.NCCCC[C@H](N)C(O)=O NWZSZGALRFJKBT-KNIFDHDWSA-N 0.000 description 1
- QFLWZFQWSBQYPS-AWRAUJHKSA-N (3S)-3-[[(2S)-2-[[(2S)-2-[5-[(3aS,6aR)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoylamino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-[1-bis(4-chlorophenoxy)phosphorylbutylamino]-4-oxobutanoic acid Chemical compound CCCC(NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)CCCCC1SC[C@@H]2NC(=O)N[C@H]12)C(C)C)P(=O)(Oc1ccc(Cl)cc1)Oc1ccc(Cl)cc1 QFLWZFQWSBQYPS-AWRAUJHKSA-N 0.000 description 1
- DSSYKIVIOFKYAU-XCBNKYQSSA-N (R)-camphor Chemical compound C1C[C@@]2(C)C(=O)C[C@@H]1C2(C)C DSSYKIVIOFKYAU-XCBNKYQSSA-N 0.000 description 1
- 125000004502 1,2,3-oxadiazolyl group Chemical group 0.000 description 1
- 125000004511 1,2,3-thiadiazolyl group Chemical group 0.000 description 1
- JYEUMXHLPRZUAT-UHFFFAOYSA-N 1,2,3-triazine Chemical compound C1=CN=NN=C1 JYEUMXHLPRZUAT-UHFFFAOYSA-N 0.000 description 1
- 125000001399 1,2,3-triazolyl group Chemical group N1N=NC(=C1)* 0.000 description 1
- 150000004907 1,2,4,5-tetrazines Chemical class 0.000 description 1
- 125000004514 1,2,4-thiadiazolyl group Chemical group 0.000 description 1
- 125000001376 1,2,4-triazolyl group Chemical group N1N=C(N=C1)* 0.000 description 1
- 125000004506 1,2,5-oxadiazolyl group Chemical group 0.000 description 1
- XXBQLHATYQHJQC-UHFFFAOYSA-N 1,2-dihydroquinoxaline Chemical compound C1=CC=C2N=CCNC2=C1 XXBQLHATYQHJQC-UHFFFAOYSA-N 0.000 description 1
- 125000005918 1,2-dimethylbutyl group Chemical group 0.000 description 1
- UPNNXUSUOSTIIM-UHFFFAOYSA-N 1,2-dithietane Chemical compound C1CSS1 UPNNXUSUOSTIIM-UHFFFAOYSA-N 0.000 description 1
- QTYUSOHYEPOHLV-FNORWQNLSA-N 1,3-Octadiene Chemical compound CCCC\C=C\C=C QTYUSOHYEPOHLV-FNORWQNLSA-N 0.000 description 1
- VDFVNEFVBPFDSB-UHFFFAOYSA-N 1,3-dioxane Chemical compound C1COCOC1 VDFVNEFVBPFDSB-UHFFFAOYSA-N 0.000 description 1
- WNXJIVFYUVYPPR-UHFFFAOYSA-N 1,3-dioxolane Chemical compound C1COCO1 WNXJIVFYUVYPPR-UHFFFAOYSA-N 0.000 description 1
- ABADUMLIAZCWJD-UHFFFAOYSA-N 1,3-dioxole Chemical compound C1OC=CO1 ABADUMLIAZCWJD-UHFFFAOYSA-N 0.000 description 1
- IMLSAISZLJGWPP-UHFFFAOYSA-N 1,3-dithiolane Chemical compound C1CSCS1 IMLSAISZLJGWPP-UHFFFAOYSA-N 0.000 description 1
- QVFHFKPGBODJJB-UHFFFAOYSA-N 1,3-oxathiane Chemical compound C1COCSC1 QVFHFKPGBODJJB-UHFFFAOYSA-N 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- KVGZZAHHUNAVKZ-UHFFFAOYSA-N 1,4-Dioxin Chemical compound O1C=COC=C1 KVGZZAHHUNAVKZ-UHFFFAOYSA-N 0.000 description 1
- HQGYGGZHZWXFSI-UHFFFAOYSA-N 1,4-cycloheptadiene Chemical compound C1CC=CCC=C1 HQGYGGZHZWXFSI-UHFFFAOYSA-N 0.000 description 1
- LGACUMPRRMLUFZ-UHFFFAOYSA-N 1,4-dihydroquinazoline Chemical compound C1=CC=C2CN=CNC2=C1 LGACUMPRRMLUFZ-UHFFFAOYSA-N 0.000 description 1
- 150000008121 1,4-dithiins Chemical class 0.000 description 1
- CPRVXMQHLPTWLY-UHFFFAOYSA-N 1,4-oxathiine Chemical compound O1C=CSC=C1 CPRVXMQHLPTWLY-UHFFFAOYSA-N 0.000 description 1
- VYXHVRARDIDEHS-UHFFFAOYSA-N 1,5-cyclooctadiene Chemical compound C1CC=CCCC=C1 VYXHVRARDIDEHS-UHFFFAOYSA-N 0.000 description 1
- 239000004912 1,5-cyclooctadiene Substances 0.000 description 1
- VMLKTERJLVWEJJ-UHFFFAOYSA-N 1,5-naphthyridine Chemical compound C1=CC=NC2=CC=CN=C21 VMLKTERJLVWEJJ-UHFFFAOYSA-N 0.000 description 1
- 150000005055 1,5-naphthyridines Chemical class 0.000 description 1
- 150000005056 1,6-naphthyridines Chemical class 0.000 description 1
- 150000005057 1,7-naphthyridines Chemical class 0.000 description 1
- 150000005058 1,8-naphthyridines Chemical class 0.000 description 1
- 125000006218 1-ethylbutyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])[H] 0.000 description 1
- BTQZKHUEUDPRST-UHFFFAOYSA-N 1-fluoro-3-methylbenzene Chemical compound CC1=CC=CC(F)=C1 BTQZKHUEUDPRST-UHFFFAOYSA-N 0.000 description 1
- 125000006039 1-hexenyl group Chemical group 0.000 description 1
- 125000006048 1-methyl-2-pentenyl group Chemical group 0.000 description 1
- 125000006052 1-methyl-3-pentenyl group Chemical group 0.000 description 1
- 125000006055 1-methyl-4-pentenyl group Chemical group 0.000 description 1
- 125000004806 1-methylethylene group Chemical class [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
- 125000006023 1-pentenyl group Chemical group 0.000 description 1
- 125000004214 1-pyrrolidinyl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- HECLRDQVFMWTQS-RGOKHQFPSA-N 1755-01-7 Chemical compound C1[C@H]2[C@@H]3CC=C[C@@H]3[C@@H]1C=C2 HECLRDQVFMWTQS-RGOKHQFPSA-N 0.000 description 1
- FJRPOHLDJUJARI-UHFFFAOYSA-N 2,3-dihydro-1,2-oxazole Chemical compound C1NOC=C1 FJRPOHLDJUJARI-UHFFFAOYSA-N 0.000 description 1
- 150000005059 2,6-naphthyridines Chemical class 0.000 description 1
- 150000005060 2,7-naphthyridines Chemical class 0.000 description 1
- ZOAMZFNAPHWBEN-UHFFFAOYSA-N 2-$l^{1}-oxidanylpropane Chemical compound CC(C)[O] ZOAMZFNAPHWBEN-UHFFFAOYSA-N 0.000 description 1
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 1
- UXGVMFHEKMGWMA-UHFFFAOYSA-N 2-benzofuran Chemical compound C1=CC=CC2=COC=C21 UXGVMFHEKMGWMA-UHFFFAOYSA-N 0.000 description 1
- 125000000069 2-butynyl group Chemical group [H]C([H])([H])C#CC([H])([H])* 0.000 description 1
- NHWQMJMIYICNBP-UHFFFAOYSA-N 2-chlorobenzonitrile Chemical compound ClC1=CC=CC=C1C#N NHWQMJMIYICNBP-UHFFFAOYSA-N 0.000 description 1
- 125000006176 2-ethylbutyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(C([H])([H])*)C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000006040 2-hexenyl group Chemical group 0.000 description 1
- 125000006049 2-methyl-2-pentenyl group Chemical group 0.000 description 1
- 125000006053 2-methyl-3-pentenyl group Chemical group 0.000 description 1
- 125000006056 2-methyl-4-pentenyl group Chemical group 0.000 description 1
- 125000004493 2-methylbut-1-yl group Chemical group CC(C*)CC 0.000 description 1
- ILPBINAXDRFYPL-UHFFFAOYSA-N 2-octene Chemical compound CCCCCC=CC ILPBINAXDRFYPL-UHFFFAOYSA-N 0.000 description 1
- 125000006024 2-pentenyl group Chemical group 0.000 description 1
- 125000001494 2-propynyl group Chemical group [H]C#CC([H])([H])* 0.000 description 1
- ZPSJGADGUYYRKE-UHFFFAOYSA-N 2H-pyran-2-one Chemical compound O=C1C=CC=CO1 ZPSJGADGUYYRKE-UHFFFAOYSA-N 0.000 description 1
- OALHHIHQOFIMEF-UHFFFAOYSA-N 3',6'-dihydroxy-2',4',5',7'-tetraiodo-3h-spiro[2-benzofuran-1,9'-xanthene]-3-one Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC(I)=C(O)C(I)=C1OC1=C(I)C(O)=C(I)C=C21 OALHHIHQOFIMEF-UHFFFAOYSA-N 0.000 description 1
- LHAMNQGGGDUVFZ-UHFFFAOYSA-N 3,4-dihydrodiazete Chemical compound C1CN=N1 LHAMNQGGGDUVFZ-UHFFFAOYSA-N 0.000 description 1
- 125000000474 3-butynyl group Chemical group [H]C#CC([H])([H])C([H])([H])* 0.000 description 1
- 125000006050 3-methyl-2-pentenyl group Chemical group 0.000 description 1
- 125000006054 3-methyl-3-pentenyl group Chemical group 0.000 description 1
- 125000006057 3-methyl-4-pentenyl group Chemical group 0.000 description 1
- YHQXBTXEYZIYOV-UHFFFAOYSA-N 3-methylbut-1-ene Chemical compound CC(C)C=C YHQXBTXEYZIYOV-UHFFFAOYSA-N 0.000 description 1
- 125000003542 3-methylbutan-2-yl group Chemical group [H]C([H])([H])C([H])(*)C([H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- XMIIGOLPHOKFCH-UHFFFAOYSA-N 3-phenylpropionic acid Chemical class OC(=O)CCC1=CC=CC=C1 XMIIGOLPHOKFCH-UHFFFAOYSA-N 0.000 description 1
- WEQPBCSPRXFQQS-UHFFFAOYSA-N 4,5-dihydro-1,2-oxazole Chemical compound C1CC=NO1 WEQPBCSPRXFQQS-UHFFFAOYSA-N 0.000 description 1
- 125000006042 4-hexenyl group Chemical group 0.000 description 1
- 125000006051 4-methyl-2-pentenyl group Chemical group 0.000 description 1
- 125000003119 4-methyl-3-pentenyl group Chemical group [H]\C(=C(/C([H])([H])[H])C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000006058 4-methyl-4-pentenyl group Chemical group 0.000 description 1
- 125000006043 5-hexenyl group Chemical group 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 108010022579 ATP dependent 26S protease Proteins 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 206010001580 Albuminuria Diseases 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 102000015427 Angiotensins Human genes 0.000 description 1
- 108010064733 Angiotensins Proteins 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- NOWKCMXCCJGMRR-UHFFFAOYSA-N Aziridine Chemical compound C1CN1 NOWKCMXCCJGMRR-UHFFFAOYSA-N 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 1
- BSYVWJYWJMFKSW-UHFFFAOYSA-N C(C)(C)(C)OC(C(C)(C)C)(OOCCCCC)OC(C)CC Chemical compound C(C)(C)(C)OC(C(C)(C)C)(OOCCCCC)OC(C)CC BSYVWJYWJMFKSW-UHFFFAOYSA-N 0.000 description 1
- AKICOOCGDHCVPT-UHFFFAOYSA-N C1=CC=CC=CC1.N1C=CC=CC=C1 Chemical compound C1=CC=CC=CC1.N1C=CC=CC=C1 AKICOOCGDHCVPT-UHFFFAOYSA-N 0.000 description 1
- HKVGLVBQYVEJRZ-UHFFFAOYSA-N CC=C.O=C=O Chemical compound CC=C.O=C=O HKVGLVBQYVEJRZ-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- 241000723346 Cinnamomum camphora Species 0.000 description 1
- 208000016998 Conn syndrome Diseases 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- DSLZVSRJTYRBFB-LLEIAEIESA-N D-glucaric acid Chemical compound OC(=O)[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O DSLZVSRJTYRBFB-LLEIAEIESA-N 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
- AEMOLEFTQBMNLQ-AQKNRBDQSA-N D-glucopyranuronic acid Chemical class OC1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-AQKNRBDQSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 206010014418 Electrolyte imbalance Diseases 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- 206010016825 Flushing Diseases 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- 230000005526 G1 to G0 transition Effects 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 229940127336 Hormone Receptor Agonists Drugs 0.000 description 1
- 208000002682 Hyperkalemia Diseases 0.000 description 1
- WRYCSMQKUKOKBP-UHFFFAOYSA-N Imidazolidine Chemical compound C1CNCN1 WRYCSMQKUKOKBP-UHFFFAOYSA-N 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 241000254158 Lampyridae Species 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 239000005089 Luciferase Substances 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-L Malonate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- MHABMANUFPZXEB-UHFFFAOYSA-N O-demethyl-aloesaponarin I Natural products O=C1C2=CC=CC(O)=C2C(=O)C2=C1C=C(O)C(C(O)=O)=C2C MHABMANUFPZXEB-UHFFFAOYSA-N 0.000 description 1
- ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical compound C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 229920002230 Pectic acid Polymers 0.000 description 1
- PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Natural products C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- KDCGOANMDULRCW-UHFFFAOYSA-N Purine Natural products N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
- 108700008625 Reporter Genes Proteins 0.000 description 1
- 235000019485 Safflower oil Nutrition 0.000 description 1
- CGMDPTNRMYIZTM-UHFFFAOYSA-N Sarohornene Natural products CC=CC=CC=CC CGMDPTNRMYIZTM-UHFFFAOYSA-N 0.000 description 1
- 206010039808 Secondary aldosteronism Diseases 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- RAHZWNYVWXNFOC-UHFFFAOYSA-N Sulphur dioxide Chemical group O=S=O RAHZWNYVWXNFOC-UHFFFAOYSA-N 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
- PSLUFJFHTBIXMW-WYEYVKMPSA-N [(3r,4ar,5s,6s,6as,10s,10ar,10bs)-3-ethenyl-10,10b-dihydroxy-3,4a,7,7,10a-pentamethyl-1-oxo-6-(2-pyridin-2-ylethylcarbamoyloxy)-5,6,6a,8,9,10-hexahydro-2h-benzo[f]chromen-5-yl] acetate Chemical compound O([C@@H]1[C@@H]([C@]2(O[C@](C)(CC(=O)[C@]2(O)[C@@]2(C)[C@@H](O)CCC(C)(C)[C@@H]21)C=C)C)OC(=O)C)C(=O)NCCC1=CC=CC=N1 PSLUFJFHTBIXMW-WYEYVKMPSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 125000003647 acryloyl group Chemical group O=C([*])C([H])=C([H])[H] 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- WNLRTRBMVRJNCN-UHFFFAOYSA-L adipate(2-) Chemical compound [O-]C(=O)CCCCC([O-])=O WNLRTRBMVRJNCN-UHFFFAOYSA-L 0.000 description 1
- 210000004404 adrenal cortex Anatomy 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 150000001342 alkaline earth metals Chemical class 0.000 description 1
- 150000001336 alkenes Chemical class 0.000 description 1
- AEMOLEFTQBMNLQ-BKBMJHBISA-N alpha-D-galacturonic acid Chemical compound O[C@H]1O[C@H](C(O)=O)[C@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-BKBMJHBISA-N 0.000 description 1
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 229910021502 aluminium hydroxide Inorganic materials 0.000 description 1
- 159000000013 aluminium salts Chemical class 0.000 description 1
- 229910000329 aluminium sulfate Inorganic materials 0.000 description 1
- 239000002416 angiotensin derivative Substances 0.000 description 1
- 125000005428 anthryl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C3C(*)=C([H])C([H])=C([H])C3=C([H])C2=C1[H] 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 229940009098 aspartate Drugs 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- GFZWHAAOIVMHOI-UHFFFAOYSA-N azetidine-3-carboxylic acid Chemical class OC(=O)C1CNC1 GFZWHAAOIVMHOI-UHFFFAOYSA-N 0.000 description 1
- 150000003851 azoles Chemical class 0.000 description 1
- RFRXIWQYSOIBDI-UHFFFAOYSA-N benzarone Chemical compound CCC=1OC2=CC=CC=C2C=1C(=O)C1=CC=C(O)C=C1 RFRXIWQYSOIBDI-UHFFFAOYSA-N 0.000 description 1
- 229940077388 benzenesulfonate Drugs 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
- 125000005605 benzo group Chemical group 0.000 description 1
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 1
- QRUDEWIWKLJBPS-UHFFFAOYSA-N benzotriazole Chemical compound C1=CC=C2N[N][N]C2=C1 QRUDEWIWKLJBPS-UHFFFAOYSA-N 0.000 description 1
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 125000001246 bromo group Chemical group Br* 0.000 description 1
- 125000006309 butyl amino group Chemical group 0.000 description 1
- 125000006251 butylcarbonyl group Chemical group 0.000 description 1
- 125000000480 butynyl group Chemical group [*]C#CC([H])([H])C([H])([H])[H] 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 229960000846 camphor Drugs 0.000 description 1
- 229930008380 camphor Natural products 0.000 description 1
- 229950005953 camsilate Drugs 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 125000005708 carbonyloxy group Chemical group [*:2]OC([*:1])=O 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 125000003016 chromanyl group Chemical group O1C(CCC2=CC=CC=C12)* 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 208000020832 chronic kidney disease Diseases 0.000 description 1
- WCZVZNOTHYJIEI-UHFFFAOYSA-N cinnoline Chemical compound N1=NC=CC2=CC=CC=C21 WCZVZNOTHYJIEI-UHFFFAOYSA-N 0.000 description 1
- 150000001854 cinnolines Chemical class 0.000 description 1
- 229940121657 clinical drug Drugs 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 239000012230 colorless oil Substances 0.000 description 1
- 229940125898 compound 5 Drugs 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 125000001352 cyclobutyloxy group Chemical group C1(CCC1)O* 0.000 description 1
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 230000006837 decompression Effects 0.000 description 1
- 238000001212 derivatisation Methods 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- YRTMEEURRDTMST-UHFFFAOYSA-N diazetidine Chemical compound C1CNN1 YRTMEEURRDTMST-UHFFFAOYSA-N 0.000 description 1
- TXCDCPKCNAJMEE-UHFFFAOYSA-N dibenzofuran Chemical group C1=CC=C2C3=CC=CC=C3OC2=C1 TXCDCPKCNAJMEE-UHFFFAOYSA-N 0.000 description 1
- 235000013681 dietary sucrose Nutrition 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- 229940043237 diethanolamine Drugs 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- ASQQEOXYFGEFKQ-UHFFFAOYSA-N dioxirane Chemical compound C1OO1 ASQQEOXYFGEFKQ-UHFFFAOYSA-N 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- VFNGKCDDZUSWLR-UHFFFAOYSA-L disulfate(2-) Chemical compound [O-]S(=O)(=O)OS([O-])(=O)=O VFNGKCDDZUSWLR-UHFFFAOYSA-L 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 201000000523 end stage renal failure Diseases 0.000 description 1
- 210000001729 epithelial cell of sweat gland Anatomy 0.000 description 1
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 125000004494 ethyl ester group Chemical group 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 125000004672 ethylcarbonyl group Chemical group [H]C([H])([H])C([H])([H])C(*)=O 0.000 description 1
- 125000006125 ethylsulfonyl group Chemical group 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 239000012065 filter cake Substances 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 150000003948 formamides Chemical class 0.000 description 1
- 150000004675 formic acid derivatives Chemical class 0.000 description 1
- 229940050411 fumarate Drugs 0.000 description 1
- 150000002240 furans Chemical class 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 229940050410 gluconate Drugs 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- MNWFXJYAOYHMED-UHFFFAOYSA-M heptanoate Chemical compound CCCCCCC([O-])=O MNWFXJYAOYHMED-UHFFFAOYSA-M 0.000 description 1
- IPCSVZSSVZVIGE-UHFFFAOYSA-M hexadecanoate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 description 1
- FUZZWVXGSFPDMH-UHFFFAOYSA-M hexanoate Chemical compound CCCCCC([O-])=O FUZZWVXGSFPDMH-UHFFFAOYSA-M 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000003707 hexyloxy group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])O* 0.000 description 1
- 108091008039 hormone receptors Proteins 0.000 description 1
- IKDUDTNKRLTJSI-UHFFFAOYSA-N hydrazine monohydrate Substances O.NN IKDUDTNKRLTJSI-UHFFFAOYSA-N 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 1
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 1
- MSQACBWWAIBWIC-UHFFFAOYSA-N hydron;piperazine;chloride Chemical compound Cl.C1CNCCN1 MSQACBWWAIBWIC-UHFFFAOYSA-N 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
- 150000002460 imidazoles Chemical class 0.000 description 1
- 125000002632 imidazolidinyl group Chemical group 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 1
- 150000002475 indoles Chemical class 0.000 description 1
- 238000009776 industrial production Methods 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 1
- VQTUBCCKSQIDNK-UHFFFAOYSA-N iso-butene Natural products CC(C)=C VQTUBCCKSQIDNK-UHFFFAOYSA-N 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- AWJUIBRHMBBTKR-UHFFFAOYSA-N isoquinoline Chemical compound C1=NC=CC2=CC=CC=C21 AWJUIBRHMBBTKR-UHFFFAOYSA-N 0.000 description 1
- 125000005956 isoquinolyl group Chemical group 0.000 description 1
- ZLTPDFXIESTBQG-UHFFFAOYSA-N isothiazole Chemical compound C=1C=NSC=1 ZLTPDFXIESTBQG-UHFFFAOYSA-N 0.000 description 1
- 150000002545 isoxazoles Chemical class 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- VTHJTEIRLNZDEV-UHFFFAOYSA-L magnesium dihydroxide Chemical compound [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 description 1
- 239000000347 magnesium hydroxide Substances 0.000 description 1
- 229910001862 magnesium hydroxide Inorganic materials 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 229940049920 malate Drugs 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 125000002950 monocyclic group Chemical group 0.000 description 1
- 125000002757 morpholinyl group Chemical group 0.000 description 1
- 239000012452 mother liquor Substances 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- KVBGVZZKJNLNJU-UHFFFAOYSA-N naphthalene-2-sulfonic acid Chemical class C1=CC=CC2=CC(S(=O)(=O)O)=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-N 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- 125000005447 octyloxy group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])O* 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 229940100688 oral solution Drugs 0.000 description 1
- PXQPEWDEAKTCGB-UHFFFAOYSA-N orotic acid Chemical compound OC(=O)C1=CC(=O)NC(=O)N1 PXQPEWDEAKTCGB-UHFFFAOYSA-N 0.000 description 1
- 150000004866 oxadiazoles Chemical class 0.000 description 1
- 150000003891 oxalate salts Chemical class 0.000 description 1
- CQDAMYNQINDRQC-UHFFFAOYSA-N oxatriazole Chemical class C1=NN=NO1 CQDAMYNQINDRQC-UHFFFAOYSA-N 0.000 description 1
- ATYBXHSAIOKLMG-UHFFFAOYSA-N oxepin Chemical compound O1C=CC=CC=C1 ATYBXHSAIOKLMG-UHFFFAOYSA-N 0.000 description 1
- 239000003973 paint Substances 0.000 description 1
- 239000003182 parenteral nutrition solution Substances 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 125000003538 pentan-3-yl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])[H] 0.000 description 1
- YWAKXRMUMFPDSH-UHFFFAOYSA-N pentene Chemical compound CCCC=C YWAKXRMUMFPDSH-UHFFFAOYSA-N 0.000 description 1
- 125000004675 pentylcarbonyl group Chemical group C(CCCC)C(=O)* 0.000 description 1
- JRKICGRDRMAZLK-UHFFFAOYSA-L peroxydisulfate Chemical compound [O-]S(=O)(=O)OOS([O-])(=O)=O JRKICGRDRMAZLK-UHFFFAOYSA-L 0.000 description 1
- 125000005561 phenanthryl group Chemical group 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 150000003020 phtalazines Chemical class 0.000 description 1
- 125000004592 phthalazinyl group Chemical group C1(=NN=CC2=CC=CC=C12)* 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- SIOXPEMLGUPBBT-UHFFFAOYSA-N picolinic acid Chemical compound OC(=O)C1=CC=CC=N1 SIOXPEMLGUPBBT-UHFFFAOYSA-N 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000003880 polar aprotic solvent Substances 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 238000007867 post-reaction treatment Methods 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 208000013846 primary aldosteronism Diseases 0.000 description 1
- 150000003141 primary amines Chemical class 0.000 description 1
- ULWHHBHJGPPBCO-UHFFFAOYSA-N propane-1,1-diol Chemical class CCC(O)O ULWHHBHJGPPBCO-UHFFFAOYSA-N 0.000 description 1
- 201000001474 proteinuria Diseases 0.000 description 1
- 238000010926 purge Methods 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 150000003217 pyrazoles Chemical class 0.000 description 1
- 125000003072 pyrazolidinyl group Chemical group 0.000 description 1
- PBMFSQRYOILNGV-UHFFFAOYSA-N pyridazine Chemical compound C1=CC=NN=C1 PBMFSQRYOILNGV-UHFFFAOYSA-N 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- 150000003233 pyrroles Chemical class 0.000 description 1
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 1
- 125000005493 quinolyl group Chemical group 0.000 description 1
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 1
- 230000006340 racemization Effects 0.000 description 1
- 229910052704 radon Inorganic materials 0.000 description 1
- SYUHGPGVQRZVTB-UHFFFAOYSA-N radon atom Chemical compound [Rn] SYUHGPGVQRZVTB-UHFFFAOYSA-N 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 235000005713 safflower oil Nutrition 0.000 description 1
- 239000003813 safflower oil Substances 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 150000003335 secondary amines Chemical class 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 1
- AWUCVROLDVIAJX-GSVOUGTGSA-N sn-glycerol 3-phosphate Chemical compound OC[C@@H](O)COP(O)(O)=O AWUCVROLDVIAJX-GSVOUGTGSA-N 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 235000013599 spices Nutrition 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 108020003113 steroid hormone receptors Proteins 0.000 description 1
- 102000005969 steroid hormone receptors Human genes 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 229960004793 sucrose Drugs 0.000 description 1
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 238000001308 synthesis method Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 125000006253 t-butylcarbonyl group Chemical group [H]C([H])([H])C(C(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- LPQZERIRKRYGGM-UHFFFAOYSA-N tert-butyl pyrrolidine-1-carboxylate Chemical class CC(C)(C)OC(=O)N1CCCC1 LPQZERIRKRYGGM-UHFFFAOYSA-N 0.000 description 1
- CBXCPBUEXACCNR-UHFFFAOYSA-N tetraethylammonium Chemical compound CC[N+](CC)(CC)CC CBXCPBUEXACCNR-UHFFFAOYSA-N 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- QEMXHQIAXOOASZ-UHFFFAOYSA-N tetramethylammonium Chemical compound C[N+](C)(C)C QEMXHQIAXOOASZ-UHFFFAOYSA-N 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 229950004288 tosilate Drugs 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 150000003852 triazoles Chemical class 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- ZDPHROOEEOARMN-UHFFFAOYSA-M undecanoate Chemical compound CCCCCCCCCCC([O-])=O ZDPHROOEEOARMN-UHFFFAOYSA-M 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 210000003556 vascular endothelial cell Anatomy 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/08—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing alicyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims (1)
- 权 利 要 求 、 其药学上可接受的盐或其异构体,其中, Cy1为 C3-8环烷基、 杂芳基或芳基;Cy2为 C3-8环烷基、 C5-8环烯基或 3-8元杂环基, 所述的 C3-8环烷基、 C5-8 环婦基和 3-8元杂环基可任选被 1、 2、 3、 4、 5或 6个独立地选自以下的取 代基取代: 卤素原子、 氰基、 羟基、 、 ·½、 C1-6烷基、 卤代 C1-6烷基、 苯基、 ( 3.8环烷基和 3-8元杂环基;L为 C(0)、 C(0)0、 C(0)NH、 NHC(0)、 NHC(0)NH、 NHS(0)、 HS(0)2、 s(o)或 s(o)2;X为 N或 CH;Rla为氢原子、 卤素原子、 、 硝基、 羟基、 、 羧基、 甲磺酰基、 甲氧羰基;Rlb为鹵素原子、 tt、 羟基、 羧基、 ^ 硝基、 巯基、 磺«、 氨基 甲酰基、 C1-6烷基、 ( 1-6烷^^、 C3-8环烷基、 C2_6烯基、 ( 5-8环烯基、 C2-6炔 基、 C3-8环烷 、 C1-6烷基胺基、 二 (C1-6烷基)胺基、 C1-6烷硫基、 烷基 羰基、 烷基胺基甲酰基、 烷基酰胺基、 烷基磺酰基、 c1-6烷基胺 基磺酰基、 C 烷基磧酰胺基、 二 (C 烷基)胺基曱酰基、 二 (C 烷基)胺基磺 酰基、 烷氧羰基或 C1-6烷基羰氧基, 所述的 烷基、 c3-8环烷基、 c2-6 烯基、 C5-8环烯基、 C2_6炔基、 C1-6烷氧基、 C3-8环烷氧基、 烷基胺基、 二 (C 烷基)胺基、 C 烷硫基、 C 烷基羰基、 C 烷基胺基甲酰基、 C 烷基 酰胺基、 烷基磺酰基、 C1-6烷基胺基磺酰基、 烷基磺酰胺基、 二 (Cw 烷基)胺基甲酰基、 二 (Cw烷基)胺基磺酰基、 C1-6烷氧羰基和 _6烷基羰氧 基可任选被 1、 2、 3、 4、 5或 6个独立地选自以下的取代基取代: 卤素原子、 、 羟基、 ½和 ^, n为 0〜4的整数, 其中 n为 2、 3或者 4时, Rlb 代表的基团可以相同或不同;R2a为氢原子、 C1-6烷基、 C3-8环烷基、 C5-8环烯基、 苯基或 3-8元杂环基, 所述的 烷基、 C3-8环烷基、 C5-8环烯基、 苯基和 3-8元杂环基可任选被 1、 2、 3、 4、 5或 6个独立地选自以下的取代基取代: 鹵素原子、 氰基、 羟基、 、 tt、 烷基和卤代 烷基;R2b、 R3a、 R3b分别独立地为氢原子、 硝基、 氰基、 卤素原子、 C1-6烷基、 烷氧基、 C3-8环烷基、 C2-6烯基、 C5-8环烯基、 C2-6块基或 C3-8环烷氧基, 所述的 烷基、 C3-8环烷基、 C2_6烯基、 C5-8环烯基、 C2_6炔基、 C1-6烷氧基 和 C3-8环烷氧基可任选被 1、 2、 3、 4、 5或 6个独立地选自以下的取代基取 代: 卤素原子、 、 羟基、 «和«;R4和 R5与它们所连接的 X形成 C3-8环烷基、 C5-8环烯基、 苯基、 3-8元 杂环基、 5-10元稠环基、 5-12元螺环基和 6-10元桥环基,所述的 C3-8环坑基、 C5-8环烯基、 苯基、 3-8元杂环基、 5-10元稠环基、 5-12元螺环基和 6-10元 桥环基可任选被 1、 2、 3或 4个独立地选自 R4a和 R5 々取代基取代;R4a为硝基、 、 卤素原子、 羟基、 ½、 烷基、 烷氧 基、 C3-8环烷基、 C2_e烯基、 C5-8环烯基、 C2 块基或 C3-8环烷氧基, 所述的 烷基、 ( 3-8环烷基、 烯基、 C5-8环烯基、 C2_e炔基、 烷氧基和 C3-8 环烷氧基可任选被 1、 2、 3、 4、 5或 6个独立地选自以下的取代基取代: 卤 素原子、 氰基、 羟基、 羧基和氨基;!^为^!^)^6,其中 R6为 OR7、C(0)R7、C(0)OR7、OC(0)R7、C(0)NR8R9、 NR8C(0)R7、 N 8R9、 S(0)qR7、 NHCOOR7、 NHCONR8R9、 S(0)q R8R9 , R8S(0)qR7或 C(0) HS(0)qR7;R7、 R8和 R9分别独立地为氢原子, C1-6烷基或 C3-8环烷基, R8和 R9可 以与它们所连接的氮形成 3-8元杂环基, 所述 C1-6烷基、 C3-8环烷基和 3-8元 杂环基可任选被 1、 2、 3、 4、 5或 6个独立地选自以下的取代基取代: 卤素 原子、 ·½、吡咯烷基、 OR10、 C(O)R10、 C(O)OR10、 OC(O)R10、 C(0)NRuR12、 NR"R12、 NRnC(0)R10, S(O)qR10、 S C^N ^R12和 NRUS C qR10;R1G、 R11和 R12分别独立地为氢原子、 C 烷基、 C3-8环烷基或苯基, R11 和 R12可以与它们所连接的氮形成 3-8元杂环基,所述 C1-6烷基、 C3-8环烷基、 苯基和 3-8元杂环基可任选被 1、 2、 3、 4、 5或 6个独立地选自以下的取代 基取代: 卤素原子、 ^&、 羟基和羧基;p为 0~6的整数;q为 0~2的整数。 、 其药学上可接受的盐或其异构体,其中, Cy1为 3-8元杂环基、 C3-8环烷基或芳基;Cy2为 C3-8环烷基、 C5-8环烯基或 3-8元杂环基, 所述的 C3-8环烷基、 C5-8 环締基和 3-8元杂环基可任选被 1、 2、 3、 4、 5或 6个独立地选自以下的取 代基取代: 卤素原子、 、 羟基、 、 、 烷基、 卤代 烷基、 苯基、 C 8环烷基和 3-8元杂环基;L为 C(0)、 C(0)0、 C(0)NH、 NHC(0)、 S(O)或 S(0)2;X为 N或 CH;R1为卤素原子、 、 羟基、 ½、 硝基、 巯基、 磺^^ 甲酰基、 烷基、 烷 ½、 C3-8环烷基、 烯基、 C5-8环烯基、 C2-6炔 基、 C3-8环烷 、 烷基胺基、 二 (Cw烷基)胺基、 烷硫基、 烷基 羰基、 烷基胺基甲酰基、 烷基酰胺基、 烷基磺酰基、 C1-6烷基胺 基横酰基、 C 烷基磺酰胺基、 二 烷基)胺基甲酰基、 二 (C 烷基)胺基磺 酰基、 烷氧羰基或 烷基羰氧基, 所述的 C1-6烷基、 C3_8环烷基、 C2-6 烯基、 C5-8环烯基、 C2_6炔基、 烷氧基、 C3-8环烷氧基、 烷基胺基、 二 烷基)胺基、 C 烷硫基、 C1-6烷基羰基、 烷基胺基甲酰基、 C 烷基 酰胺基、 烷基磺酰基、 Cw烷基胺基磺酰基、 烷基横酰胺基、 二 (Cw 烷基)胺基曱酰基、 二 (Q_6烷基)胺基磺酰基、 Ci.6烷氧羰基和 C1-6烷基羰氧 基可任选被 1、 2、 3、 4、 5或 6个独立地选自以下的取代基取代: 鹵素原子、 ·½、 羟基、 和 ^, m为 0〜5的整数, 其中 R1相同或不同;R2a为氢原子、 烷基、( 3-8环烷基、 C5-8环烯基、 苯基或 3-8元杂环基, 所述的 d_6烷基、 C3-8环烷基、 (5-8环烯基、 苯基和 3-8元杂环基可任选被 1、 2、 3、 4、 5或 6个独立地选自以下的取代基取代: 卤素原子、 氰基、 羟基、 、 tt、 烷基和卤代 C1-6烷基;R2b、 1 分别独立地为氢原子、 硝基、 氰基、 卤素原子、 烷基、 C1-6 烷氧基、 C3-8环烷基、 C2-6烯基、 C5-8环烯基、 C2_6块基或 C3-8环烷氧基, 所 述的 C1-6烷基、 C3-8环烷基、 C2-6烯基、 C5-8环浠基、 C2_6炔基、 烷氧基和 C3-8环烷氧基可任选被 1、 2、 3、 4、 5或 6个独立地选自以下的取代基取代: 卤素原子、 氰基、 羟基、 和氨基; R4和 R5与它们所连接的 X形成 C3-8环烷基、 ( 5-8环烯基、 苯基或 3-8元 杂环基, 所述的 C3-8环烷基、 C5-8环烯基、 苯基和 3-8元杂环基可任选被 1、 2、 3或 4个独立地选自 R4a和 R5a的取代基取代;1 43为硝基、 、 卤素原子、 羟基、 、 tt、 烷基、 烷氧 基、 C3-8环烷基、 C2_6烯基、 C5-8环烯基、 C2_6炔基或 C3-8环烷氧基, 所述的 烷基、 C3-8环烷基、 C2 烯基、 C5-8环烯基、 炔基、 烷氧基和 C3-8 环烷氧基可任选被 1、 2、 3、 4、 5或 6个独立地选自以下的取代基取代: 卤 素原子、 氰基、 羟基、 羧基和氨基;R5a为 (CH2)pR6,其中 R6为 OR7、 C(0)R7、 C(0)OR7、 OC(0)R7、 C(0)NR8R9、 NR8C(0)R7、 NR8R9、 S(0)qR7、 NHCOOR7、 NHCONR8R9、 S(0)qNR8R9、 NR8S(0)qR7或 C(0)NHS(0)qR7;R7、 R8和 R9分别独立地为氢原子, C1-6烷基或 C3-8环烷基, R8和 R9可 以与它们所连接的氮形成 3-8元杂环基, 所述 烷基、 C3-8环烷基和 3-8元 杂环基可任选被 1、 2、 3、 4、 5或 6个独立地选自以下的取代基取代: 卤素 原子、氰基、吡咯烷基、 OR10, C(0)R1G、 C(0)OR1Q、 OC(0)R1G、 C(0)NRuR12、 "R12、 NRnC(0)R10, S(0)qR10. S(0)q uR12和 NRUs R10;R1G、 R11和 R12分别独立地为氢原子、 烷基、 C3-8环烷基或苯基, R11 和 R12可以与它们所连接的氮形成 3-8元杂环基,所述 Cw烷基、 C3-8环烷基、 苯基和 3-8元杂环基可任选被 1、 2、 3、 4、 5或 6个独立地选自以下的取代 基取代: 卤素原子、 、 羟基和羧基;p为 0~6的整数;q为 0〜2的整数。3、 如权利要求 2所述的化合物、 其药学上可接受的盐或其异构体, 其中, Cy1为苯基、 吡吱基或嘧啶基;Cy2为 C^8环烷基或 3-8元杂环基, 所述的 C3-8环烷基和 3-8元杂环基可 任选被 1、 2、 3、 4、 5或 6个独立地选自以下的取代基取代: 卤素原子、 氰 基、 羟基、 羧基、 ½、 C1-6烷基、 卤代 d-6烷基、 笨基、 C3-8环烷基和 3-8 元杂环基;L为 C(O), C(0)0, C(0)NH、 NHC(O)或 S(0)2;X为 N或 CH;R1为卤素原子、 «、 羟基、 ½、磺 、 C1-6烷基、 C1-6烷 tt、 C3-8 环烷基、 C2_6烯基、 C2_e炔基、 C1-6烷基胺基、 二 (C1-6烷基)胺基、 烷基胺 基甲酰基、 C 烷基酰胺基、 烷基磺酰基、 烷基胺基磺酰基、 烷 基磺酰胺基、 烷氧羰基或 C 烷基羰氣基,所述的 CW烷基、 烷氧基、 C3-8环烷基、 C2_6烯基、 C2_6炔基、 C1-6烷基胺基、 二 (C^烷基)胺基、 C1-6烷 基胺基甲酰基、 C 烷基酰胺基、 C 烷基磺酰基、 C 烷基胺基磺酰基、 Ci-6 烷基横酰胺基、 C1-6烷氧羰基和 烷基羰氧基可任选被 1、 2、 3或 4个独立 地选自以下的取代基取代: 卤素原子、 、 羟基、 羧基和氨基, m为 0~3 的整数, 其中 R1相同或不同;R2a为氢原子、 C3-8环烷基、 C5-8环烯基、 苯基或 3-8元杂环基, 所述的 C3-8环烷基、 C5-8环烯基、 苯基和 3-8元杂环基可任选被 1、 2、 3、 4、 5或 6 个独立地选自以下的取代基取代: 卤素原子、 、 羟基、 羧基、 氨基、 C1-6 烷基和鹵代 C 烷基;R2b、 1 3£1分别独立地为氢原子、 、 卤素原子、 烷基、 烷氧基、C 8环烷基或 C2-e炔基, 所述的 烷基、 烷氧基、 C3-8环烷基或 C2_6炔 基和可任选被 1、 2、 3、 4、 5或 6个独立地选自以下的取代基取代: 卤素原 子、 氰基、 羟基、 羧基和氨基;R4和 R5与它们所连接的 X形成 C3_8环烷基、 C5-8环烯基或 3-8元杂环基, 所述的 C3-8环烷基、 C5-8环烯基和 3-8元杂环基可任选被 1、 2或 3个独立地 选自 R4a和 R5a的取代基取代;为硝基、 、 卤素原子、 羟基、 、 C 烷基、 烷 、 C3-8 环烷基、 C2_e烯基或 C2_e炔基, 所述的 C 烷基、 _6烷氧基、 C3-8环烷基、 C2_6烯基和 C2_6炔基可任选被 1、 2、 3、 4、 5或 6个独立地选自以下的取代基 取代: 卤素原子、 、 羟基、 羧基和R5a为(CH2)pR6, 其中 R6为 OR7、 C(0)OR7、 OC(0)R7、 C(0)N 8R9、 NR8C(0)R7、 NR8R9、 S(0)qR7、 NHCON V, S(0)qNR8R9, NR8S(0)qR7或 C(0)NHS(0)qR7;R7、 R8和 R9分别独立地为氢原子、 烷基或 C3-8环烷基, R8和 R9可 以与它们所连接的氮形成 3-8元杂环基, 所述 C1-6烷基、 C3-8环烷基和 3-8元 杂环基可任选被 1、 2、 3、 4、 5或 6个独立地选自以下的取代基取代: 卤素 原子、 tt、吡咯烷基、 OR10, C(O)OR10、 OC(O) R10, C(0)NRnR12, NRnR12、 NRnC(O)R10> S(0)qR10, S ^qNRUR12和R1Q、 R11和 R12分别独立地为氢原子、 烷基或 C3-8环烷基, R11和 R12 可以与它们所连接的氮形成 3-8元杂环基, 所述 烷基、 C^8环烷基和 3-8 元杂环基可任选被 1、 2、 3、 4、 5或 6个独立地选自以下的取代基取代: 卤 素原子、 氰基、 羟基和羧基;p为 0~4的整数;q为 0〜2的整数。4、 如权利要求 2所述的化合物、 其药学上可接受的盐或其异构体, 其中, Cy1为笨基或吡啶基;Cy2为 C5_e环烷基或 3-8元杂环基, 所述的 C5_6环烷基和 3-8元杂环基可 任选被 1、 2、 3、 4、 5或 6个独立地选自以下的取代基取代: 卤素原子、 氰 基、 羟基、 羧基、 tt、 C 烷基、 卤代 _6烷基、 苯基、 C3-8环烷基和 5-7 元杂环基;L为 C(0)、 C(0)0、 NHC(O)或 C(0)NH;X为 N或 CH;R1为氢原子、 卤素原子、 氰基、 羟基、 羧基、 磺酸基、 烷基、 烷 、 ( 3-8环烷基、 C2_e炔基、 C1-6烷基胺基、 二 (Cw烷基)胺基、 d.6烷基 胺基甲酰基、 烷基酰胺基、 烷基胺基磺酰基、 烷基磺酰胺基、 C1-6 烷氧羰基或 烷基羰氧基, 所述的 烷基、 C3-8环烷基、 C2_6炔基、 C1-6 烷 tt、 C1-6烷基胺基、 二 (Cw烷基)胺基、 C1-6烷基胺基甲酰基、 烷基酰 胺基、 C 烷基胺基磺酰基、 烷基磺酰胺基、 C 烷氧羰基和 C 烷基羰 氧基可任选被 1、 2、 3或 4个独立地选自以下的取代基取代: 卤素原子、 氰 基、 羟基、 羧基和氨基, m为 1~3的整数, 其中 R1相同或不同;R2a为氢原子、 C3-8环烷基、 苯基、 C^6环烯基、 或 4-7元杂环基, 所述的 C3-8环烷基、 苯基、 C5_6环烯基和 4-7元杂环基可任选被 1、 2、 3或 4个独立 地选自以下的取代基取代: 卤素原子、 、 羟基、 羧基、 tt、 d_6烷基和 鹵代 烷基;R2b、 R3a分别独立地为氢原子、 ·½、 卤素原子、 烷基、 C 烷!^ 或 C2_6炔基, 所迷的 烷基、 Cw烷氧基和 C2_e块基可任选被 1、 2、 3或 4 个独立地选自以下的取代基取代: 卤素原子、 氰基、 羟基、 羧基和氨基;R4和 R5与它们所连接的 X形成 C3-8环烷基或 3-8元杂环基, 所述的 C3_8 环烷基和 3-8元杂环基可任选被 1或 2个独立地选自 R4a和 R5a的取代基取代;1 43为"½、 卤素原子、 羟基、 氨基、 烷基、 烷 «~或 C3-8环烷 基, 所述的 C 烷基、 烷氧基和 C3-8环烷基可任选被 1、 2、 3或 4个独立 地选自以下的取代基取代: 卤素原子、 tt、 羟基、 羧基和氨基;R5a为 (CH2)pR6, 其中 R6为 OR7、 C(0)OR7、 OC(0)R7、 C(0)NR8R9、 NR8C(0)R7、 NR8R9或 NHCONR8R9;R7、 R8和 R9分别独立地为氢原子、 C1-6烷基或 C4-7环烷基, R8和 R9可 以与它们所连接的氮形成 4-7元杂环基, 所述 烷基、 C4j环烷基和 4-7元 杂环基可任选被 1、 2、 3或 4个独立地选自以下的取代基取代: 卤素原子、 氰基、 OR1Q、 C(0)OR1Q、 OC(0)R1Q、 C(0)NR"R12、 N NR12 , NR'^^R10 和 S(0)QR10;R1Q、 R1 1和 R12分别独立地为氢原子、 烷基或 C4-7环烷基, 所述 C1-6 烷基和 Ομ7环烷基可任选被 1、 2、 3、 4、 5或 6个独立地选自以下的取代基 取代: 卤素原子、 、 羟基和羧基;ρ为 0~4的整数;q为 0~2的整数。5、 如权利要求 2所述的化合物、 其药学上可接受的盐或其异构体, 其中, Cy1为苯基;Cy2为 3-8元杂环基或 C5_6环烷基, 所述的 3-8元杂环基和 环烷基可 任选被 1、 2、 3、 4、 5或 6个独立地选自以下的取代基取代: 卤素原子、 氰 基、 羟基、 羧基、 tt、 C^e烷基、 卤代 烷基、 苯基、 C4_6环烷基和 4-6 元杂环基;L为 C(0)、 C(0)NH、 NHC(O)或 C(0)0;X为 N或 CH;R1为氢原子、 卤素原子、 氰基、 羟基、 羧基、 磺酸基、 烷基、 C 8 环烷基、 C2_6块基、 烷基胺基曱酰基、 烷基酰胺基、 烷基胺基磺 酰基、 C 烷基磺酰胺基、 C 烷氧羰基或 C 烷基羰氧基,所述的 C 烷基、 C3-8环烷基、 C2_e炔基、 烷基胺基甲酰基、 烷基酰胺基、 C1-6烷基胺基 磺酰基、 烷基磺酰胺基、 烷氧羰基和 烷基羰氧基可任选被 1、 2、 3或 4个独立地选自以下的取代基取代: 卤素原子、 氰基、 羟基、 羧基和氨 基, m为 1~2的整数, 其中 R1相同或不同;R2A为氢原子、 苯基、 C5_6环浠基、 5-6元杂环基或 环烷基, 所述的苯 基、 C5_6环烯基、 5-6元杂环基和 Cue环烷基可任选被 1、 2、 3或 4个独立地 选自以下的取代基取代: 卤素原子、 氰基、 羟基、 、 氨基、 烷基和卤 代 Ci_6坑基;R2B、 R3A分别独立地为氢原子、 氰基、 卤素原子或 CM烷基, 所述的 CM 烷基可任选被 1、 2、 3或 4个独立地选自以下的取代基取代: 卤素原子、 氰 基、 羟基、 羧基和氨基;R4和 R5与它们所连接的 X形成 C4_6环烷基或 4-6元杂环基, 所述的 C4 环烷基和 4-6元杂环基可任选被 1或 2个独立地选自 R4A和 R5A的取代基取代;11½为 、 卤素原子、 羟基、 、 烷基或 烷 所述的 烷基和 烷氧基可任选被 1、 2、 3或 4个独立地选自以下的取代基取代: 卤素原子、 氰基、 羟基、 和氨基;R5A为(CH2)p 6, 其中 R6为 OR7、 C(0)OR7、 OC(0)R7、 NR8C(0)R7、 C(0) R7R8或 NR8R9;R7、 R8和 R9分别独立地为氢原子、 C1-6烷基或 C4-7环烷基, 所述 烷 基和 C4-7环烷基可任选被 1、 2、 3或 4个独立地选自以下的取代基取代: 鹵 素原子、 、 OR10, C(O)OR10、 OC(O)R10、 C NRUR12和 NRUR12;R1Q、 R11和 R12分别独立地为氢原子或 CM烷基, 所述 烷基可任选被 1、 2、 3或 4个独立地选自以下的取代基取代: 卤素原子、 氰基、 羟基和羧 基;p为 0~3的整数。6、 如权利要求 2所述的化合物、 其药学上可接受的盐或其异构体,1为笨基;地选自以下的取代基取代: 卤素原子、 、 羟基、 羧基、 CM烷基和 卤代 CM烷基;L为 C(0)、 C(0)NH、 NHC(O)或 C(0)0;X为 N;R1为卤素原子、 、 羟基、 羧基、 C3环烷基、 乙炔基、 C 烷基胺基 甲酰基、 或 烷基, 所述的 C 烷基可任选被 1、 2、 3或 4个独立地选自 以下的取^ ^取代: 卤素原子、 、 羟基、 和氨基, m为 1或 2, 其 中 R1相同或不同;R2a为氢原子、 苯基、 C 环烯基、 5-6元杂环基、 环丁基、 环戊基或环己 基, 所述的苯基、 环婦基、 5-6元杂环基、 环丁基、 环戊基和环己基可任 选被 1、 2、 3或 4个独立地选自以下的取代基取代: 卤素原子、 氰基、 羟基、 、 _3烷基和卤代 C1-3烷基;R2b、 R3a分别独立地为氢原子、 氰基、 卤素原子或 CM烷基所述的 CM 烷基可任选被 1、 2、 3或 4个独立地选自以下的取代基取代: 卤素原子、 氰 基、 羟基、 羧基和氨基;R4和 R5与它们所连接的 N形成 4-6元杂环基, 所述的 4-6元杂环基可任 选被 烷基和 /或 R5a取代;R5a为 (CH2)pR6, 其中 R6为 OR7、 OC(0)R7、 C(0)NR7R8或 N 8R9;R7、 R8和 R9分别独立地为氢原子或 烷基,所述 CM烷基可任选被 1、 2、 3或 4个独立地选自以下的取代基取代: 卤素原子、 、 OR10. C(0)OR10 和 RUR12;R1Q、 R11和 R12分别独立地为氢原子或 CM烷基, 所述 CM烷基可任选被 1、 2、 3、 4、 5或 6个独立地选自以下的取代基取代: 卤素原子、 氰基、 羟 基和羧基;p为 0或 1。7、 如权利要求 2所述的化合物、 其药学上可接受的盐或其异构体,1为苯基;可任选被 1、 2或 3个独立地选自以下的取代基取代: 卤素原子、氰基、羟基、 、 、 甲基、 乙基和三氟甲基;L为 C(0)、 NH(CO)或 C(0)NH;X为 N;R1为氟原子、 氯原子、 氰基、 甲基、 乙基、 异丙基、 三氟曱基、 环丙基、 羟基、 乙炔基、 甲基胺基甲酰基或羟甲基, m为 1或 2, 其中 R1相同或不同;R2a为环戊基、 苯基、 环戊烯基、 吡咯基、 哌啶基、 环丁基, 所述的环戊 基、 苯基、 环戊烯基、 吡咯基、 哌啶基、 环丁基可任选被 1、 2或 3个独立地 选自以下的取代基取代: 卤素原子、 氰基、 羟基、 、 氨基、 (^_3烷基和卤 代 C1-3烷基;R2b、 R3a分别独立地为氢原子、 、 卤素原子、 甲基、 乙基、 异丙基、 三氟甲基、 羟甲基或氨甲基;R4和 R5与它们所连接的 N形成环己基、 哌啶基, 所述的环己基和哌啶 基可任选被 烷基和 /或 R5a取代;R5a为 (CH2)pR6, 其中 R6为 OR7、 OC(0)R7、 C(0) 7R8或 NR8R9;R7、 R8和 R9分别独立地为氢原子或(^3烷基,所述 Cw烷基可任选被 1、 2或 3个独立地选自以下的取代基取代: 卤素原子、 氰基、 羟基和 NR"R12;R11 R12分别独立地为氢原子、 甲基、 乙基或异丙基;p为 0。8、 如权利要求 2所述的化合物、 其药学上可接受的盐或其异构体,1为苯基;甲基和乙基;L为 C(O)或 NH(CO);X为 N或 CH;R1独立地选自氟原子、 氯原子、 氰基、 甲基、 乙基、 异丙基、 环丙基、 羟基、 乙炔基、 和曱基胺基曱酰基, m为 1或 2, 其中 m为 2时, R1相同或 不同;R2a为环戊基、 环戊烯基、 环丁基、 苯基、 哌啶基或吡咯基, 所述的环戊 基、 环戊烯基、 环丁基、 苯基、 哌啶基和吡咯基可任选被 1、 2或 3个独立地 选自卤素原子的取代基取代:R2b为氢原子; R3a为氢原子、 甲基或乙基;R4和 R5与它们所连接的 X形成哌啶基或环己基, 所述的环己基和哌啶 基可任选被羟基、 甲基、 乙基、 tt、 氨基羰基、 曱基甲酰氧基、 乙基甲酰 氧基、 曱氧基和乙氧基中的一或两个取代基取代。9、 如权利要求 2所述的化合物、 其药学上可接受的盐或其异构体,1为苯基;L为 C(O)或 NHC(O);X为 N或 CH;R1彼此独立地选自氯原子、 氰基、 甲基、 乙基、 异丙基、 环丙基、 羟基、 乙炔基、 和曱基胺基甲酰基, m为 1或 2, 其中 m为 2时 R1相同或不同;R2a为环戊基、 环戊烯基、 环丁基、 苯基、 哌啶基或吡咯基; 所述的环戊 基、 环戊浠基、 环丁基、 苯基、 哌啶基和吡咯基可任选被 1、 2或 3个独立地 选自卤素原子的取 取代:R2b和 R3a为氢原子;R4和 R5与它们所连接的 X形成哌啶基或环己基, 所述的环己基和哌啶 基可任选被羟基、 曱基、 乙基、 、 氨基羰基、 曱基甲酰氧基、 乙基甲酰 氣基、 甲氧基和乙氧基中的一或两个取 基取代。10、 如权利要求 2所述的化合物、 其药学上可接受的盐或其异构体, 其中, Cy1为苯基;CL为 C(O);X为 N;R1彼此独立地选自氯原子、 ^、 甲基,m为 2;1^为环戊基R2b和 R3a为氢原子;R4和 R5与它们所连接的 X形成 4-羟基哌啶基。药学上可接受的12、 通式( Ila )所示的化合物或其药学上可接受的盐,其中, R2b为氢, R2a如权利要求 1所述, 但不能为氢, Cy Cy2, L X、 Rla、 Rlb、 R3a、 R3b、 R4、 R5和 n如权利要求 1所述。物或其药学上可接受的盐,其中, Cy Cy2、 L、 X、 R1, R2a、 R2b、 R3a、 R4、 R5和 m如权利要求 2 所述。14、含有权利要求 1〜13任一项所述的化合物、其药学上可接受的盐或其 异构体的药物制剂, 其特征在于包括一种或多种药用载体。15、含有权利要求 1〜13任一项所述的化合物、其药学上可接受的盐或其 异构体在制备治疗和 /或预防肾损伤和 /或心血管疾病包括高血压、 心力衰竭、 心肌梗塞、 心绞痛、 心脏肥大、 心肌炎、 心脏血管纤维化、 压力感受器官能 障碍、 过多的体液和心律不齐, 或内分泌疾病, 包括原发 /继发性醛 酮增多 症、 阿狄森氏病、 库兴氏综合症和巴特式综合症的药物中的应用。16、 药物组合物, 其特征在于包含权利要求 1-13任一项所述的化合物、 其药学上可接受的盐或其异构体和一种或多种治疗活性物质, 所述治疗活性 物质选自血管紧张素 II拮抗剂或其药学上可接受的盐; HMG-Co-A还原酶抑 制剂或其药学上可接受的盐; 钙通道阻滞剂(CCB )或其药学上可接受的盐; 血管紧张素转化酶 /中性内肽酶(ACE/NEP )双重抑制剂或其药学上可接受的 盐; 抗糖尿病药; 减肥药; 醛固酮受体阻滞剂; 内皮素受体阻滞剂; CETP 抑制剂; Na-K-ATP酶膜泵抑制剂; β -肾上腺素能受体抑制剂或 α -肾上腺素 能受体阻断剂; 中性内肽酶(ΝΕΡ )抑制剂和变力剂。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201180031781.5A CN103052632B (zh) | 2010-08-18 | 2011-08-18 | 二氢吡唑类化合物 |
Applications Claiming Priority (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201010256527.2 | 2010-08-18 | ||
CN201010256527 | 2010-08-18 | ||
CN201010549656.0 | 2010-11-12 | ||
CN201010549656 | 2010-11-12 | ||
CN201110080789 | 2011-03-23 | ||
CN201110080789.2 | 2011-03-23 | ||
CN201180031781.5A CN103052632B (zh) | 2010-08-18 | 2011-08-18 | 二氢吡唑类化合物 |
PCT/CN2011/001378 WO2012022120A1 (zh) | 2010-08-18 | 2011-08-18 | 二氢吡唑类化合物 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN103052632A true CN103052632A (zh) | 2013-04-17 |
CN103052632B CN103052632B (zh) | 2014-03-19 |
Family
ID=45604725
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201180031781.5A Active CN103052632B (zh) | 2010-08-18 | 2011-08-18 | 二氢吡唑类化合物 |
Country Status (2)
Country | Link |
---|---|
CN (1) | CN103052632B (zh) |
WO (1) | WO2012022120A1 (zh) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20180280414A1 (en) | 2015-10-13 | 2018-10-04 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Methods and pharmaceutical compositions for the treatment of choroidal neovascularisation |
ES2973248T3 (es) | 2016-07-26 | 2024-06-19 | Inst Nat Sante Rech Med | Antagonista del receptor mineralocorticoide para el tratamiento de la osteoartritis |
JP2023518168A (ja) | 2020-03-11 | 2023-04-28 | アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル | 対象が中心性漿液性脈絡網膜症を有するか、または有する危険性があるかどうかを決定する方法。 |
WO2023031277A1 (en) | 2021-08-31 | 2023-03-09 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for the treatment of ocular rosacea |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101541785A (zh) * | 2006-10-26 | 2009-09-23 | 拜耳先灵制药股份公司 | 取代二氢吡唑啉酮和它们作为hif-脯氨酰-4-羟化酶抑制剂的用途 |
WO2009129945A1 (de) * | 2008-04-23 | 2009-10-29 | Bayer Schering Pharma Aktiengesellschaft | Substituierte dihydropyrazolone als hemmer der hif-prolyl-4-hydroxylase |
CN101600710A (zh) * | 2006-10-26 | 2009-12-09 | 拜耳先灵制药股份公司 | 取代的二吡啶基二氢吡唑啉酮和它们的应用 |
-
2011
- 2011-08-18 CN CN201180031781.5A patent/CN103052632B/zh active Active
- 2011-08-18 WO PCT/CN2011/001378 patent/WO2012022120A1/zh active Application Filing
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101541785A (zh) * | 2006-10-26 | 2009-09-23 | 拜耳先灵制药股份公司 | 取代二氢吡唑啉酮和它们作为hif-脯氨酰-4-羟化酶抑制剂的用途 |
CN101600710A (zh) * | 2006-10-26 | 2009-12-09 | 拜耳先灵制药股份公司 | 取代的二吡啶基二氢吡唑啉酮和它们的应用 |
WO2009129945A1 (de) * | 2008-04-23 | 2009-10-29 | Bayer Schering Pharma Aktiengesellschaft | Substituierte dihydropyrazolone als hemmer der hif-prolyl-4-hydroxylase |
Also Published As
Publication number | Publication date |
---|---|
CN103052632B (zh) | 2014-03-19 |
WO2012022120A1 (zh) | 2012-02-23 |
WO2012022120A8 (zh) | 2013-02-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN113272301B (zh) | 杂环类化合物、中间体、其制备方法及应用 | |
AU2023202086A1 (en) | Antagonists of the muscarinic acetylcholine receptor M4 | |
EP2590974B1 (en) | Tetrahydro-pyrido-pyrimidine derivatives | |
CA2859764C (en) | Dihydro-benzo-oxazine and dihydro-pyrido-oxazine derivatives | |
EA035823B1 (ru) | 1,1,1-трифтор-3-гидроксипропан-2-ил карбаматные производные и 1,1,1-трифтор-4-гидроксибутан-2-ил карбаматные производные в качестве ингибиторов magl | |
EP3019478B1 (en) | Fused piperidine amides as modulators of ion channels | |
AU2012328561A1 (en) | Benzoxazolinone compounds with selective activity in voltage-gated sodium channels | |
CN103547577A (zh) | 作为盐皮质激素受体拮抗剂的并环类化合物 | |
AU2017359027A1 (en) | Indazole derivatives as αV integrin antagonists | |
EP2516439A1 (en) | Diaza-spiro[5.5]undecanes as orexin receptor antagonists | |
CN106414439B (zh) | 作为食欲素受体拮抗剂的哌啶衍生物 | |
BR112021003496A2 (pt) | composto, composição farmacêutica, e, métodos para tratar doença cardíaca, para tratar uma doença ou afecção associada à cardiomiopatia hipertrófica, ou afecção que está associada ao espessamento secundário da parede do ventrículo esquerdo, ou afecção que está associada à pequena cavidade do ventículo esquerdo e obliteração da cavidade, contração hiperdinâmica do ventrículo esquerdo, isquemia miocárdica ou fibrose cardíaca, ou afecção selecionada dentre distrofias musculares e doenças de armazenamento de glicogênio, para inibir o sarcômero cardíaco | |
AU2019233183A1 (en) | Phthalazine isoxazole alkoxy derivatives, preparation method thereof, pharmaceutical composition and use thereof | |
CN104487434B (zh) | 双环取代的嘧啶类化合物 | |
WO2021216951A1 (en) | Condensed substituted hydropyrroles as antagonists of the muscarinic acetylcholine receptor m4 | |
CN103052632A (zh) | 二氢吡唑类化合物 | |
CA2679346A1 (en) | Tricyclic isoquinoline derivatives for treatment of obesity | |
AU2019280356B2 (en) | ERK inhibitor and use thereof | |
NZ301264A (en) | 4-(1-heteroaryl substituted-piperidinyl)-1h-indole derivatives and medicaments | |
CN103965167A (zh) | 咪唑羧酸衍生物 | |
CN106632243A (zh) | 吡咯烷衍生物 | |
EP3619200A1 (en) | Heterocyclic p2x7 antagonists | |
EP2391617B1 (en) | Azetidines as histamine h3 receptor antagonists | |
CN112313222B (zh) | 四氢异喹啉类衍生物、其制备方法及其用途 | |
WO2002053568A1 (fr) | Inhibiteurs de la biosynthese du cholesterol contenant comme principe actif des composes spiro tricycliques |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
C56 | Change in the name or address of the patentee | ||
CP02 | Change in the address of a patent holder |
Address after: 250101 Shandong city of Ji'nan province high tech Zone Hong Xing three North Road No. 2 building 401 Ji'nan trough Patentee after: KBP BIOSCIENCES Co.,Ltd. Address before: 250101 Shandong city of Ji'nan province high tech Zone Shun Road No. 750 University Science Park B302 Patentee before: KBP BIOSCIENCES Co.,Ltd. |
|
TR01 | Transfer of patent right |
Effective date of registration: 20230915 Address after: 02-00, 80 Lo Min Shen Road, Singapore Patentee after: KBP Pharmaceutical Technology Singapore Address before: 250101 Room 401, building 2, Jinan Yaogu, north section of Gangxing Third Road, high tech Zone, Jinan City, Shandong Province Patentee before: KBP BIOSCIENCES Co.,Ltd. |
|
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20240222 Address after: Denmark bagsvaerd Patentee after: NOVO NORDISK A/S Country or region after: Denmark Address before: 80 Ramin Shin Road, Singapore 02-00 Patentee before: KBP Pharmaceutical Technology Singapore Country or region before: Singapore |
|
TR01 | Transfer of patent right |